Drugs / PATECIBART
PATECIBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04503733 | Oct 2020 → Oct 2022 | pulmonary arterial hypertension | Gmax Biopharm LLC. | Unknown | No outcome recorded |
| Phase 1 | NCT04505137 | Sep 2020 → Mar 2021 | pulmonary arterial hypertension | Gmax Biopharm Australia Pty Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PATECIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314760 ↗ |
| Known as | Getagozumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314760 ↗ |
| Known as | GMA301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04503733 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314760 ↗ |
| Route | Intravenous | “Q4W GMA301 IV injections (300 mg)” NCT04503733 ↗ |